A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease (PRECiSE 4)
Crohn's Disease
About this trial
This is an interventional treatment trial for Crohn's Disease
Eligibility Criteria
Inclusion Criteria: Participation in either of the CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] clinical studies in which the subject completed the Week 2 assessment in CDP870-031 [NCT00152490] or the Week 6 randomization in CDP870-032 [NCT00152425] but whose Crohn's Disease was significantly worse as determined by the investigator and whose Clinical Disease Activity Index (CDAI) score at entry to this study is either (subjects may have received active or placebo treatment): At least 70 points higher then Baseline (Week 0 CDP870-031 [NCT00152490]; Week 6 CDP870 032 [NCT00152425] responders) OR Higher than Baseline (Week 0 CDP870-031 [NCT00152490]; Week 6 CDP870-032 [NCT00152425] responders) with an absolute score of at least 350 points Subjects must be able to understand the information provided to them and give written informed consent Exclusion Criteria: Any exclusion criterion that would have prevented the subject's participation in the qualifying pivotal study (CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]), although the upper limit of 450 in the CDAI score is not applicable. In addition the criterion that excludes previous participation in a clinical trial of Certolizumab Pegol does not apply
Sites / Locations
- 45102
- 45028
- 45044
- 45095
- 45101
- 45130
- 45094
- 45005
- 45087
- 45004
- 45016
- 45037
- 45019
- 45033
- 45013
- 45083
- 45108
- 45035
- 45009
- 45070
- 45145
- 45067
- 45003
- 45040
- 45081
- 45091
- 45054
- 45025
- 45039
- 45041
- 45093
- 45113
- 45119
- 45022
- 45073
- 45139
- 45052
- 45134
- 45078
- 45109
- 45141
- 11011
- 11005
- 11017
- 11006
- 11014
- 11016
- 11007
- 11002
- 11013
- 11012
- 11009
- 11010
- 11015
- 11018
- 46006
- 46003
- 46002
- 12001
- 13004
- 13001
- 13003
- 15001
- 16005
- 16014
- 16013
- 16008
- 18006
- 18001
- 18004
- 18002
- 19004
- 19009
- 19010
- 19007
- 19003
- 20001
- 20002
- 22002
- 22009
- 22004
- 22019
- 22013
- 22017
- 22015
- 22016
- 22001
- 22012
- 22008
- 24002
- 24009
- 24011
- 26004
- 26007
- 26005
- 27001
- 27004
- 27007
- 31002
- 31001
- 31005
- 31004
- 31003
- 32005
- 32008
- 32004
- 33008
- 33003
- 33018
- 33013
- 33007
- 33009
- 34017
- 34006
- 34016
- 34001
- 34005
- 34007
- 34013
- 35001
- 35002
- 35004
- 36002
- 38001
- 38003
- 39013
- 39003
- 39016
- 39018
- 39012
- 39010
- 39008
- 39004
- 39006
- 39009
- 39014
- 39019
- 40009
- 43008
- 43003
- 43006
Arms of the Study
Arm 1
Experimental
Certolizumab Pegol
3-dose induction regimen of Certolizumab Pegol 400 mg at Weeks 0, 2, 4. Subsequently continue on 4-weekly treatment with Certolizumab Pegol 400 mg until Week 360.